2. Search Result
Search Result
Results for "

Intravenous injection

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

2

MCE Kits

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10225
    Thielavin A

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
    Thielavin A
  • HY-B1657
    Fosphenytoin

    		Drug Intermediate Neurological Disease
    Fosphenytoin is a phosphate ester proagent developed as an alternative to intravenous phenytoin for acute intervention of seizures. Fosphenytoin has advantages including more convenient and rapid intravenous administration, availability for intramuscular injection, and low potential for adverse local reactions at injection sites .
    Fosphenytoin
  • HY-105236
    (Rac)-Enadoline

    (Rac)-CI-977 free base

    		 Opioid Receptor Neurological Disease
    (Rac)-Enadoline ((Rac)-CI-977 free base) is a selective K-opioid receptor agonist that stereoselectively antagonizes clonic seizures induced by slow intravenous injection of N-methyl-DL-aspartate in mice .
    (Rac)-Enadoline
  • HY-B1300A
    Cefonicid

    		Bacterial Others
    Pharmacokinetic studies of Cefonicid have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
    Cefonicid
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-B1300B
    Cefonicid monosodium

    		Endogenous Metabolite Others
    Pharmacokinetic studies of Cefonicid monosodium have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .
    Cefonicid monosodium
  • HY-106258
    Atilmotin

    OHM 11638; BAX-ACC 1638; MOT 288

    		 Motilin Receptor Metabolic Disease
    OHM 11638 (Atilmotin), an analogue of the (1-14) fragment of porcine motilin, is a motilin receptor agonist with a pKd of 8.94 for the motilin receptor. OHM 11638 affects esophageal, lower esophageal sphincter (LES), and gastric motility. OHM 11638 increases LES and gastric pressures, OHM 11638 can be used as prokinetic agents .
    Atilmotin
  • HY-176027
    CP-LC-1422

    		Liposome Others
    CP-LC-1422 is a homocysteine-derived ionizable amino lipid with high RNA delivery capability and can mediate high-level protein expression in vivo. CP-LC-1422 exhibits significant spleen targeting via intravenous injection in a lipid nanoparticle (LNP) formulation with no significant toxicity observed .
    CP-LC-1422
  • HY-130522
    6β-Prostaglandin I1

    6β-PGI1

    		 Prostaglandin Receptor Others
    6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
    6β-Prostaglandin I1
  • HY-118350
    FR 75513

    		Biochemical Assay Reagents Neurological Disease
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-B2227B
    Lactate (sodium) (60% in water)
    Maximum Cited Publications
    17 Publications Verification

    Lactic acid sodium

    		 Bacterial Metabolic Disease Cancer
    Lactate (60% in water) (Lactic acid) sodium is the product of glycogenolysis and glycolysis . Lactate sodium (60% in water) is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium (60% in water) can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium (60% in water) is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium (60% in water) is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection . Lactate sodium (60% in water) also has antimicrobial activity, which can be used as a food preservative .
    Lactate (sodium) (60% in water)
  • HY-137500
    NT1-014B

    		Liposome Biochemical Assay Reagents Cardiovascular Disease Neurological Disease
    NT1-014B is a tryptamine-derived lipidoid. NT1-014B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-014B enhances brain delivery via intravenous injection. NT1-014B can be used in ischemic stroke research .
    NT1-014B
  • HY-12976
    DS-1558

    		G Protein-coupled Receptor Kinase (GRK) Metabolic Disease
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
    DS-1558
  • HY-136831
    SR2640

    QMPB

    		 Leukotriene Receptor Inflammation/Immunology
    SR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research .
    SR2640
  • HY-P0093
    Sincalide
    3 Publications Verification

    Cholecystokinin octapeptide; CCK-8; SQ19844

    		 Cholecystokinin Receptor Apoptosis PI3K Akt Infection Cancer
    Sincalide (Cholecystokinin octapeptide, CCK-8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK. Sincalide can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide
  • HY-168782
    Resolvin D2 n-3 DPA

    		TNF Receptor Interleukin Related Inflammation/Immunology
    Resolvin D2 n-3 DPA is a specialized proresolving mediator (SPM). Resolvin D2 n-3 DPA (1 nM) can reduce the chemotaxis and adhesion of human neutrophils induced by TNF-α. Resolvin D2 n-3 DPA (100 ng/mouse; intravenous injection) can reduce neutrophil infiltration in the peritoneum and the levels of IL-6 and the chemokine (C-C motif) ligand 2 (CCL2) in a mouse model of inflammation induced by zinc oxide .
    Resolvin D2 n-3 DPA
  • HY-W338446
    BF-170

    		Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-P0093A
    Sincalide ammonium
    3 Publications Verification

    Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

    		 Cholecystokinin Receptor Apoptosis PI3K Akt Infection Cancer
    Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK .
    Sincalide ammonium